ABSTRACT
PurposeRandomized controlled trials have shown the efficacy of atropine for progressive myopia, and this treatment has become the preferred pattern for this condition in Taiwan. This study explores the effectiveness of atropine 0.5% treatment for progressive high myopia and adherence to therapy in a non-Asian country.MethodsAn effectiveness study was performed in Rotterdam, the Netherlands. Overall 77 children (mean age 10.3 years±2.3), of European (n=53), Asian (n=18), and African (n=6) descent with progressive myopia were prescribed atropine 0.5% eye drops daily. Both parents and children filled in a questionnaire regarding adverse events and adherence to therapy. A standardized eye examination including cycloplegic refraction and axial length was performed at baseline and 1, 4, and 12 months after initiation of therapy.ResultsMean spherical equivalent at baseline was -6.6D (±3.3). The majority (60/77, 78%) of children adhered to atropine treatment for 12 months; 11 of the 17 children who discontinued therapy did so within 1 month after the start of therapy. The most prominent reported adverse events were photophobia (72%), followed by reading problems (38%), and headaches (22%). The progression rate of spherical equivalent before treatment (-1.0D/year±0.7) diminished substantially during treatment (-0.1D/year±0.7) compared to those who ceased therapy (-0.5D/year±0.6; P=0.03).ConclusionsDespite the relatively high occurrence of adverse events, our study shows that atropine can be an effective and sustainable treatment for progressive high myopia in Europeans.
Subject(s)
Atropine/therapeutic use , Muscarinic Antagonists/therapeutic use , Myopia, Degenerative/drug therapy , Administration, Topical , Adolescent , Atropine/adverse effects , Axial Length, Eye , Child , Disease Progression , Female , Humans , Male , Medication Adherence , Muscarinic Antagonists/adverse effects , Myopia, Degenerative/diagnosis , Myopia, Degenerative/physiopathology , Netherlands , Ophthalmic Solutions , Refraction, Ocular/physiology , Treatment Outcome , White PeopleABSTRACT
OBJECTIVE: Renal transplantation in patients with end-stage renal failure (ESRF) secondary to amyloidosis carries a high risk of postoperative complications. Preoperative investigations are crucial for a successful perioperative course. There are limited data studying the outcome of patients with amyloid nephropathy who undergo renal transplantation. Therefore, we undertook this retrospective review of our experience to highlight the difficulties. MATERIALS AND METHODS: Thirteen patients with AA amyloid-induced ESRF underwent cadaveric renal transplantation from 1985 to 2001 in the Irish transplant population. The perioperative course of these patients was compared to an age-matched control group of 142 nonamyloid patients who had cadaveric renal transplantation during the same time period. Both groups were followed annually for 5 years. RESULTS: The 1- and 5-year patient survival rates were 69% and 69% in the amyloid as compared with 97% and 87% for the control group. In the amyloid group, early death was primarily due to cardiac causes followed by complications of sepsis. Graft survival at 1 and 5 years was 56% and 56% in the amyloid group as compared with 87% and 59% in the control group (P = .0027). Four deaths with a functioning graft contributed to the early graft losses. CONCLUSION: Increased complications, especially cardiac, are noted post-renal transplantation among patients with renal amyloidosis. However, appropriate guideline, for the perioperative management of these patients has yet to be established.
